Post #13 by LucidDreamer on the Macroeconomic Trends and Risks board

Shrewd'm.com

A merry & shrewd investing community

Best Of Macro | Best Of | Favourites & Replies | All Boards | Post of the Week!

Search Macro

Shrewd'm.com Merry shrewd investors
Best Of Macro | Best Of | Favourites & Replies | All Boards | Post of the Week!

Search Macro

Please be open to feedback and constructive criticism from others, and consider their suggestions and advice when making decisions or forming opinions.

- Manlobbi

Personal Finance Topics / Macroeconomic Trends and Risks

Unthreaded | Threaded | Whole Thread (1)

Prev | Next

Post New

Post Reply | Report Post | Recommend It!

No. of Recommendations: 3

Otsuka, the Japan partner, took the expected next step of submitting the drug so they can start selling in 2025. This is expected to trigger a $20m milestone payment to Esperion, presumably here in Q4.

While expected, it is good to see things moving forward.

https://www.esperion.com/news-releases/news-releas...

Dreamer

Print the post

Post New

Unthreaded | Threaded | Whole Thread (1)

Prev | Next

Announcements

Macroeconomic Trends and Risks FAQ

Contact Shrewd'm
Contact the developer of these message boards.

Ticker or Board Name Author

A community forum supporting civilized, and highly helpful, self-educating investors that come together for Shrewdness and merry spirits. These message boards closely follow the look and feel of the old message boards at boards.fool.com prior to the boards redirected to discussion.fool.com. Shrewd'm is not affiliated with the comprehensive and excellent investment website, The Motley Fool (TMF), in any way. The Shrewd commmunity here has owed, and continues to owe, gratitude to The Motley Fool for nurturing a culture of jovial irreverence towards Wall St, and that tradition will continue here.